Pharmasite Research, Inc.

Baltimore, Maryland 21210

3 studies enrolling now · 48 studies all time

What they study most

Alzheimer Disease (AD), Alzheimer's Disease, Anxiety Disorder, Breast Neoplasms, Chronic Migraine, Depression, Depressive Disorder, Major, Episodic Migraine, Generalized Anxiety Disorder, Hot Flashes, Major Depressive Disorder, Migraine

Studies at this site

• A Study of Brenipatide in Adult Participants With Major Depressive Disorder — Recruiting now
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Recruiting now
• An Open-Label Study of Azetukalner in Major Depressive Disorder — Enrolling by invitation
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine — Stopped early
• A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight — Running, not enrolling
• A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine — Stopped early
• A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine — Running, not enrolling
• A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine — Running, not enrolling
• A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer — Running, not enrolling
• A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy — Completed
• A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD — Completed
• A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause — Completed
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2 — Completed
• Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION) — Completed
• Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) — Stopped early
• A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease — Completed
• Evaluation of Galcanezumab in the Prevention of Chronic Migraine — Completed
• Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext — Completed
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine — Completed
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
• Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD) — Completed
• Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) — Stopped early
• Study of Rapastinel as Monotherapy in Patients With MDD — Stopped early
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02) — Completed
• Open Label Extension for GLYX13-C-202, NCT01684163 — Stopped early
• A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease — Stopped early
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
• Biomarker Study in Participants With Migraine — Completed
• Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine — Completed
• A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache — Completed
• A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD — Completed
• A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD — Completed
• POC Study in Partially Responsive Generalized Anxiety Disorder — Stopped early
• A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder — Completed
• Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants — Completed
• Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — Completed
• Treatment-Resistant Depression Registry — Completed
• Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder — Completed
• Experimental Medication For the Treatment of Generalized Anxiety Disorder — Completed
• Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD) — Completed
• Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses — Completed
• A Study of Aripiprazole in Patients With Major Depressive Disorder — Completed
• The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder — Completed